November 27, 2020
Breaking breaking-news Business Coronavirus Editors' Pick Healthcare Innovation Science Technology

Pfizer-BioNTech Says Covid-19 Vaccine Is 95% Effective, Will Seek Emergency Approval Within Days

This post was originally published on this site

https://thumbor.forbes.com/thumbor/fit-in/0x0/filters:format(jpg)/https://specials-images.forbesimg.com/imageserve/5e723a3d37d0440006bcccf9/0x0.jpg

Topline

Pfizer and BioNTech are preparing to submit their Covid-19 vaccine for emergency use approval in the U.S. and the EU after new trial data showed it to be 95% effective, following initial news of 90% efficacy in its Phase 3 trials.

uncaptioned

Key Facts

New findings from Phase 3 clinical trials, which enrolled over 43,000 people to test the two-dose Covid-19 vaccine, show the vaccine to be effective at preventing Covid-19 in 95% of cases, an improvement on earlier results indicating the vaccine to be 90% effective. 

The companies say the findings are consistent across various demographics, including age, race and ethnicity, with the vaccine still more than 94% effective in adults over the age of 65.

This is a developing story, check back for updates.

Full coverage and live updates on the Coronavirus

Related Posts